Performance of DNLI Denali Therapeutics | 12% in 12m
Compare DNLI with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Denali Therapeutics with its related Sector/Index XBI
Performance Duell DNLI vs XBI
| TimeFrame | DNLI | XBI |
|---|---|---|
| 1 Week | 7.63% | 0.39% |
| 1 Month | 20.3% | 3.23% |
| 3 Months | 25.4% | 7.10% |
| 6 Months | 24.9% | 2.26% |
| 12 Months | 12.0% | 26.63% |
| YTD | 26.6% | 9.75% |
| Rel. Perf. 1m | 1.37 | |
| Rel. Perf. 3m | 3.80 | |
| Rel. Perf. 6m | 2.27 | |
| Rel. Perf. 12m | 2.27 | |
| Spearman 1m | 0.87 | 0.03 |
| Spearman 3m | 0.77 | 0.63 |
Is Denali Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (September 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -77.08 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of September 2024 is 28.46. This means that DNLI is currently overvalued and has a potential downside of 5.1% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of September 2024 is 28.46. This means that DNLI is currently overvalued and has a potential downside of 5.1% (Sold with Premium).
Is DNLI a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: DNLI is performing better - Values below 0%: DNLI is underperforming
Compare DNLI with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 7.00% | 16.28% | 15.72% | -12.79% |
| US NASDAQ 100 | QQQ | 5.89% | 16.43% | 17.40% | -13.03% |
| US Dow Jones Industrial 30 | DIA | 7.91% | 16.23% | 18.64% | -6.98% |
| German DAX 40 | DBXD | 8.99% | 16.85% | 22.00% | -3.54% |
| UK FTSE 100 | ISFU | 9.37% | 18.04% | 14.09% | -4.58% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 9.37% | 23.21% | 33.93% | 23.32% |
| Hongkong Hang Seng | HSI | 8.07% | 18.11% | 27.27% | 18.40% |
| Japan Nikkei 225 | EXX7 | 8.69% | 16.50% | 29.35% | 2.91% |
| India NIFTY 50 | INDA | 8.37% | 17.64% | 14.78% | -14.20% |
| Brasil Bovespa | EWZ | 8.91% | 21.03% | 30.94% | 15.64% |
DNLI Denali Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 8.63% | 20.44% | 17.96% | -12.68% |
| Consumer Discretionary | XLY | 5.46% | 11.38% | 19.26% | 3.02% |
| Consumer Staples | XLP | 8.41% | 15.07% | 13.60% | -5.35% |
| Energy | XLE | 11.54% | 26.37% | 28.63% | 18.66% |
| Financial | XLF | 10.20% | 15.27% | 15.19% | -16.62% |
| Health Care | XLV | 8.49% | 16.32% | 17.95% | -6.39% |
| Industrial | XLI | 7.95% | 16.51% | 18.74% | -11.38% |
| Materials | XLB | 8.44% | 17.02% | 23.28% | -0.35% |
| Real Estate | XLRE | 5.21% | 12.43% | 10.83% | -13.67% |
| Technology | XLK | 3.88% | 15.32% | 19.29% | -15.26% |
| Utilities | XLU | 7.04% | 15.45% | 2.26% | -10.51% |
| Aerospace & Defense | XAR | 8.85% | 17.81% | 16.65% | -17.19% |
| Biotech | XBI | 7.24% | 17.02% | 22.59% | -14.59% |
| Homebuilder | XHB | 7.38% | 14.56% | 15.44% | -29.41% |
| Retail | XRT | 10.13% | 20.87% | 28.14% | -4.27% |
Does Denali Therapeutics outperform its market, is DNLI a Sector Leader?
No, over the last 12 months Denali Therapeutics (DNLI) made 12.04%, while its related Sector, the SPDR S&P Biotech (XBI) made 26.63%.
Over the last 3 months DNLI made 25.37%, while XBI made 7.10%.
No, over the last 12 months Denali Therapeutics (DNLI) made 12.04%, while its related Sector, the SPDR S&P Biotech (XBI) made 26.63%.
Over the last 3 months DNLI made 25.37%, while XBI made 7.10%.
| Period | DNLI | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 20.25% | 3.23% | 3.97% |
| 3 Months | 25.37% | 7.10% | 3.59% |
| 12 Months | 12.04% | 26.63% | 24.83% |